AHS Cancer Control Alberta

🇨🇦Canada
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy

First Posted Date
2016-06-10
Last Posted Date
2019-07-05
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
13
Registration Number
NCT02795572
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

RATIO: Rational Approach To Immuno-Oncology

Not Applicable
Completed
Conditions
Metastatic Melanoma
Interventions
Procedure: Molecular Microscope Diagnostic system
First Posted Date
2016-03-07
Last Posted Date
2024-06-14
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
35
Registration Number
NCT02700971
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

APBI: 27Gy in 5 Fractions for Early Breast Cancer

Not Applicable
Conditions
Breast Cancer
Interventions
Radiation: APBI 27Gy in 5 fractions
First Posted Date
2016-02-12
Last Posted Date
2019-02-21
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
274
Registration Number
NCT02681107
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Multi-Parametric Brain Cancer MRI

Not Applicable
Completed
Conditions
Brain Tumors
Interventions
Other: 3D MRI Scans
First Posted Date
2016-01-07
Last Posted Date
2024-01-30
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
30
Registration Number
NCT02649699
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer

First Posted Date
2015-12-16
Last Posted Date
2024-08-15
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
45
Registration Number
NCT02632305
Locations
🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Rosuvastatin in the Treatment of Rectal Cancer

Phase 2
Completed
Conditions
Rectal Cancer
Interventions
Drug: Rosuvastatin
First Posted Date
2015-10-07
Last Posted Date
2022-07-20
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
45
Registration Number
NCT02569645
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients

First Posted Date
2015-05-12
Last Posted Date
2021-06-23
Lead Sponsor
AHS Cancer Control Alberta
Registration Number
NCT02439723
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib

Withdrawn
Conditions
Renal Cell Cancer
Fatigue
First Posted Date
2015-04-28
Last Posted Date
2019-07-05
Lead Sponsor
AHS Cancer Control Alberta
Registration Number
NCT02428335
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Chemoradiotherapy for Advanced Esophageal Cancer

First Posted Date
2014-11-21
Last Posted Date
2022-04-04
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
50
Registration Number
NCT02297217
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

First Posted Date
2014-11-20
Last Posted Date
2024-07-08
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
100
Registration Number
NCT02295722
Locations
🇨🇦

Tom Baker Cancer Center, Calgary, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy